Get started
Author

Despoina Papazoglou

Observed name: Papazoglou, Despoina
ORCID: 0009-0008-5818-8663
Observed ORCID: 0009-0008-5818-8663
OpenAlex ID: A5081597699
Tumor-Infiltrating Clonal Hematopoiesis
2025 · Oriol Pich, Elsa Bernard, et al. · New England Journal of Medicine · 106
Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils
2023 · Hector Huerga Encabo, Iker Valle Aramburu, et al. · Cell stem cell · 75
PDF
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
2023 · Benedetta Apollonio, Filomena Spada, et al. · Journal of Clinical Investigation · 63
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
2020 · Nikolaos Ioannou, Patrick R. Hagner, et al. · Blood · 50
Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
2019 · Hsiling Chiu, Preeti Trisal, et al. · British Journal of Haematology · 48
PDF
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia
2018 · Nikos Papakonstantinou, Stavroula Ntoufa, et al. · International Journal of Cancer · 27
PDF
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
2021 · Benedetta Apollonio, Nikolaos Ioannou, et al. · Frontiers in Oncology · 26
PDF
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities
2020 · Anna Vardi, Elisavet Vlachonikola, et al. · Clinical Cancer Research · 25
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial
2023 · Despoina Papazoglou, Xin Victoria Wang, et al. · Blood · 23
PDF
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
2023 · Francesca Arruga, Marta Rubin, et al. · Haematologica · 13
Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial
2018 · Despoina Papazoglou, Connie E. Lesnick, et al. · Blood · 11
Clonal hematopoiesis landscape in frequent blood donors
2025 · Darja Karpova, Hector Huerga Encabo, et al. · Blood · 10
Human TET2 -Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
2025 · Hector Huerga Encabo, Giuseppe D’Agostino, et al. · Blood Cancer Discovery · 9
Exploring the intricate cross-talk between clonal expansion and the bone marrow niche
2024 · Steven Ngo, Despoina Papazoglou, et al. · Frontiers in Hematology · 4
Data from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
2026 · Hector Huerga Encabo, Giuseppe D’Agostino, et al. · 3
Remodeling of the bone marrow vasculature induced by venetoclax and azacitidine damage
2026 · Steven Ngo, Giuseppe D’Agostino, et al. · Blood · 3
Mesenchymal stromal cells from JAK2 V617F myeloproliferative neoplasms support healthy and malignant hematopoiesis in a humanized scaffold model in vivo
2025 · Alessandra Ferrelli, Syed Mian, et al. · HemaSphere · 1
PDF
Differential Effects of Iberdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing
2021 · Yumi Nakayama, Hsiling Chiu, et al. · Blood · 1
Tp63 Contributes to the Apoptosis Resistant Phenotype in Aggressive Chronic Lymphocytic Leukemia
2015 · Stavroula Ntoufa, Nikos Papakonstantinou, et al. · Blood · 1
Supplementary Table S5 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
2026 · Hector Huerga Encabo, Giuseppe D’Agostino, et al.
Supplementary Table S4 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
2026 · Hector Huerga Encabo, Giuseppe D’Agostino, et al.
Supplementary Table S1 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
2026 · Hector Huerga Encabo, Giuseppe D’Agostino, et al.
Supplementary Figures S1-S7 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
2026 · Hector Huerga Encabo, Giuseppe D’Agostino, et al.
Supplementary Table S2 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
2026 · Hector Huerga Encabo, Giuseppe D’Agostino, et al.
Supplementary Table S6 from Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny
2026 · Hector Huerga Encabo, Giuseppe D’Agostino, et al.
Works count: 35
Citation count: 499
H-index: 11
I10-index: 12
Year
Topic
Type